Researchers presented a microbody recombinant decoy protein with high affinity to angiotensin-converting enzyme 2 (ACE2) as an option for coronavirus disease 2019 (COVID-19) treatment.
In a recent study published in the Journal of Clinical Ultrasound, researchers in Italy reported cardiac magnetic resonance (CMR) findings in individuals with myocarditis-like syndrome during the acute phase of SARS-CoV-2 infection (AMCovS) and post-acute phase (cPACS).